Indoco Remedies has secured final USFDA approval for its generic Lacosamide oral solution, a bioequivalent of Vimpat, enabling the company to market this essential epilepsy treatment in the US from ...

Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...

Mumbai: Indoco Remedies Ltd. has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated ...

Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.

Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. You must not be given Vimpat® if you have ever had an allergic ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to lacosamide or ...

Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...